Aristotle Capital Boston LLC Has $29.68 Million Position in Haemonetics Corporation $HAE

Aristotle Capital Boston LLC lessened its stake in shares of Haemonetics Corporation (NYSE:HAE) by 8.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 370,308 shares of the medical instruments supplier’s stock after selling 33,854 shares during the period. Haemonetics accounts for about 1.6% of Aristotle Capital Boston LLC’s portfolio, making the stock its 11th largest position. Aristotle Capital Boston LLC owned approximately 0.80% of Haemonetics worth $29,680,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. AQR Capital Management LLC lifted its position in shares of Haemonetics by 48.6% during the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after acquiring an additional 1,034,226 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Haemonetics by 994.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after buying an additional 1,254,035 shares during the last quarter. North Peak Capital Management LLC raised its holdings in Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after buying an additional 740,626 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Haemonetics by 2.5% during the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after buying an additional 26,763 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after buying an additional 755,592 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Barrington Research lowered their price objective on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $84.00 price objective on shares of Haemonetics in a report on Wednesday. Citigroup upped their price objective on shares of Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, May 28th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $78.33.

Haemonetics Stock Performance

Shares of HAE stock opened at $72.78 on Thursday. The firm has a 50-day moving average of $63.31 and a 200-day moving average of $67.15. The company has a market cap of $3.31 billion, a P/E ratio of 36.03, a P/E/G ratio of 1.50 and a beta of 0.56. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. The company had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities research analysts forecast that Haemonetics Corporation will post 5.22 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.